Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Ty
- PDF / 823,611 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 54 Downloads / 147 Views
ORIGINAL RESEARCH
Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial Li Wang . Xiangyang Liu . Wenjuan Yang . Jingbo Lai . Xinwen Yu . Jianrong Liu . Xiling Gao . Jie Ming . Kaiyan Ma . Jing Xu . Zhufang Tian . Qingzhen He . Qiuhe Ji Received: June 2, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: To compare blood glucose variability (GV) in Chinese participants with type 2 diabetes mellitus (T2DM) whose blood glucose levels are inadequately controlled with metformin monotherapy after twice-daily exenatide or biphasic insulin aspart 30 (BIAsp30). Methods: In this 16-week multicenter, randomized clinical trial, 104 participants were randomized 1:1 to receive exenatide (exenatide Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12765704. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13300020-00904-z) contains supplementary material, which is available to authorized users. L. Wang X. Liu J. Lai X. Yu J. Ming Q. Ji (&) Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi’an, China e-mail: [email protected]; [email protected]
group) or BIAsp30 (BIAsp30 group) twice daily. All participants continued metformin treatment. The primary outcome was the change in GV as measured by a continuous glucose monitoring system (CGMS) from baseline to 16 weeks. Results: At 16 weeks, both the Exenatide and BIAsp30 groups effectively decreased mean glucose (MG), but neither group changed the mean amplitude of glycemic excursion (MAGE), largest amplitude of glycemic excursion (LAGE), mean of daily difference (MODD), or standard deviation of blood glucose (SDBG). The decrease in 2-h post-breakfast glucose excursions was greater in the Exenatide group compared to the BIAsp30 group, with a least square (LS) mean difference [95% CI] of (1.58 [0.53, 2.63]). Exenatide also significantly reduced 2-h post-lunch K. Ma Department of Endocrinology, Shangluo Central Hospital, Shangluo, Shaanxi, China
W. Yang Department of Endocrinology, Shaanxi Aerospace Hospital, Xi’an, Shaanxi, China
J. Xu Department of Endocrinology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
J. Liu Department of Endocrinology, Xi’an Chang an Hospital, Xi’an, Shaanxi, China
Z. Tian Department of Endocrinology, Xi’an Central Hospital, Xi’an, Shaanxi, China
X. Gao Department of Endocrinology, Yan’an People’s Hospital, Yan’an, Shaanxi, China
Q. He Department of Endocrinology, Xi’an Gaoxin Hospital, Xi’an, Shaanxi, China
Diabetes Ther
glucose excursion compared to BIAsp30 (LS mean difference [95% CI], 1.19 [0.18, 2.20]). The Exenatide group had significantly reduced body weight and body mass index (BMI), while the BIAsp30 group had increased weight and had no change in BMI. Both treatments were well tolerated with no
Data Loading...
